BSH 2019 | The AML18 trial: addressing therapeutic questions in older patients
Steven Knapper
• 2 Apr 2019
Steven Knapper, DM, FRCPath, MRCP, BMBCh, Cardiff University, Cardiff, Wales, UK, discusses AML18 (ISRCTN31682779), a trial for older patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). The trial hopes to address several therapeutic questions, including whether there is a benefit of adding additional doses of CPX-351 into induction therapy and the significance of MRD status after the first cycle of chemotherapy. This interview took place at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.
